CCTG IND Incoming Chair Dr Yvette Drew is the incoming chair of the CCTG IND committee. She has also been principal investigator of multiple early phase to phase 3 studies. Dr Yvette Drew is a Medical Oncologist and Associate Professor at BC Cancer Centre Vancouver and the University of British Columbia. She specializes in the care and management of patients with gynecological cancers and the development and delivery of early phase clinical trials. Dr Drew joined the team in Vancouver in 2021. Prior to this she worked as a Senior Lecturer and Medical Oncologist in the UK and was the translational gyne cancer lead and the deputy lead of the Experimental Medicines Centre in Newcastle. She undertook specialist medical oncology training at the Beatson West of Scotland cancer centre, Glasgow and the Northern Centre for Cancer Care, Newcastle. During this time, she was awarded a Cancer Research UK funded PhD fellowship investigating the role of PARP inhibitors in homologous recombination deficient ovarian cancer. During her PhD she won a merit award for her research from the American Society of Clinical Oncology and was awarded the Medical Sciences doctoral prize. She has been awarded clinical trial research funding from Ovarian Cancer Canada and was recently awarded a 5 year Michael Smith Health Professional Investigator award. Alongside her work with CCTG, she is an active member of the BC Cancer GYN clinical trials group, OVCARE and GCI research community. Her goal is to develop novel therapies through early phase clinical trials in gynecological cancers. Research interests include non-cytotoxic targeted treatments and PARP inhibitor resistance.“Robust, well designed, patient centred, early phase clinical trials are a key step to progress novel discoveries in research laboratories to improving real world patient care and outcomes.”“Robust, well designed, patient centred, early phase clinical trials are a key step to progress novel discoveries in research laboratories to improving real world patient care and outcomes.”“Robust, well designed, patient centred, early phase clinical trials are a key step to progress novel discoveries in research laboratories to improving real world patient care and outcomes.”“Robust, well designed, patient centred, early phase clinical trials are a key step to progress novel discoveries in research laboratories to improving real world patient care and outcomes.”Research Interests:gynecological cancers novel therapies in gynecological malignanciesearly phase clinical trial development targeting DNA repair pathways as treatment for cancer PARP inhibitor resistance.For a list of Dr. Drew’s publications, visit on PubMed.
